Repligen Corporation (RGEN) financial statements and ratios from SEC XBRL: revenue $0.8B (TTM), net margin 6.6%, revenue growth 11.9% YoY, P/E 241.2. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $738.26M |
| Revenue (TTM) | $0.8B |
| Net Margin | 6.6% |
| Return on Equity | 2.0% |
| Operating Margin (TTM) | 8.2% |
| Debt / Equity | 0.26 |
| Current Ratio | 9.05 |
| Net Debt / EBITDA | -1.8 |
| Interest Coverage | 2.9 |
| Revenue Growth (YoY) | 11.9% |
| EPS Growth (YoY) | -65.4% |
| FCF Growth (YoY) | 27.5% |
| P/E Ratio | 241.2 |
| EV / EBITDA | 69.5 |
| Price / Book | 4.74 |
| Price / Sales | 12.76 |
| FCF Yield | 1.1% |
| Altman Z-Score | 8.01 (safe) |
| Piotroski F-Score | 7/9 |
| Piotroski checks passed | 7 of 9 |
| Industry P/E (Pharmaceutical Products) | 16.0 |
| Sector P/E (Healthcare) | 21.5 |
RGEN overview · RGEN earnings · RGEN KPIs · RGEN documents · RGEN ownership · RGEN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.